

# Nicola Fazio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/894409/publications.pdf>

Version: 2024-02-01

229  
papers

8,035  
citations

50170

46  
h-index

58464

82  
g-index

232  
all docs

232  
docs citations

232  
times ranked

8333  
citing authors

#	ARTICLE	IF	CITATIONS
1	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2016, 387, 968-977.	6.3	962
2	Peptide receptor radionuclide therapy with <sup>177</sup> Lu-DOTATATE: the IEO phase I-II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2125-2135.	3.3	349
3	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. <i>Neuroendocrinology</i> , 2017, 105, 212-244.	1.2	325
4	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. <i>Journal of Clinical Oncology</i> , 2011, 29, 2372-2377.	0.8	261
5	Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research. <i>Journal of Clinical Oncology</i> , 2007, 25, 3217-3223.	0.8	247
6	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	0.8	233
7	Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. <i>Annals of Oncology</i> , 2009, 20, 935-940.	0.6	192
8	Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma. <i>Annals of Oncology</i> , 2000, 11, 301-306.	0.6	188
9	The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. <i>Neuroendocrinology</i> , 2017, 104, 85-93.	1.2	185
10	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. <i>Neuroendocrinology</i> , 2017, 105, 266-280.	1.2	122
11	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 141-157.	2.7	119
12	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. <i>Endocrine-Related Cancer</i> , 2019, 26, 227-239.	1.6	114
13	Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors. <i>Chest</i> , 2013, 143, 955-962.	0.4	110
14	Long-term results of PRRT in advanced bronchopulmonary carcinoid. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 441-452.	3.3	103
15	Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. <i>Annals of Oncology</i> , 2021, 32, 439-451.	0.6	101
16	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. <i>Neuroendocrinology</i> , 2017, 105, 281-294.	1.2	94
17	Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. <i>Cancer Treatment Reviews</i> , 2016, 50, 61-67.	3.4	85
18	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. <i>Oncologist</i> , 2014, 19, 966-974.	1.9	84

#	ARTICLE	IF	CITATIONS
19	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , 2014, 25, 1373-1378.	0.6	84
20	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. <i>Endocrine Connections</i> , 2016, 5, 174-187.	0.8	83
21	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. <i>Annals of Oncology</i> , 2017, 28, 1309-1315.	0.6	82
22	Interferon- $\gamma$ and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. <i>Annals of Oncology</i> , 2007, 18, 13-19.	0.6	80
23	Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. <i>World Journal of Surgical Oncology</i> , 2007, 5, 73.	0.8	77
24	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. <i>Endocrine-Related Cancer</i> , 2018, 25, 583-593.	1.6	77
25	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. <i>BMC Cancer</i> , 2014, 14, 184.	1.1	76
26	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1411-1422.	5.1	74
27	Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. <i>Neuroendocrinology</i> , 2015, 101, 274-288.	1.2	72
28	Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. <i>Cancer Science</i> , 2018, 109, 174-181.	1.7	72
29	Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: Possible indications for a multimodal approach. <i>Surgery</i> , 2014, 155, 607-614.	1.0	71
30	Adjuvant colon cancer chemotherapy: where we are and where we'll go. <i>Cancer Treatment Reviews</i> , 2010, 36, S34-S41.	3.4	70
31	Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. <i>World Journal of Gastroenterology</i> , 2010, 16, 868-74.	1.4	69
32	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 453-461.	1.9	66
33	A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. <i>Anticancer Research</i> , 2016, 36, 713-9.	0.5	66
34	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. <i>Surgery</i> , 2018, 163, 761-767.	1.0	65
35	Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): A critical view. <i>Cancer Treatment Reviews</i> , 2013, 39, 270-274.	3.4	64
36	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study. <i>Cancer</i> , 2014, 120, 2457-2463.	2.0	62

#	ARTICLE	IF	CITATIONS
37	Molecularly targeted endocrine therapies for breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, S67-S71.	3.4	61
38	Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. <i>Neuroendocrinology</i> , 2016, 103, 806-814.	1.2	61
39	Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). <i>Annals of Oncology</i> , 2018, 29, viii467-viii468.	0.6	61
40	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1&G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 981-989.	0.7	58
41	ENETS Consensus Guidelines for the Management of Peritoneal Carcinomatosis from Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2010, 91, 333-340.	1.2	56
42	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2012, 96, 32-40.	1.2	55
43	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
44	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. <i>Pancreas</i> , 2017, 46, 302-305.	0.5	53
45	Neuroendocrine neoplasms of rectum: A management update. <i>Cancer Treatment Reviews</i> , 2018, 66, 45-55.	3.4	52
46	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	1.6	52
47	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq1 1 0.784314 rgBT /Overl 32		
48	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 638-638.	0.8	51
49	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	0.8	49
50	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. <i>Journal of Clinical Investigation</i> , 2016, 127, 153-168.	3.9	49
51	Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. <i>European Journal of Surgical Oncology</i> , 2017, 43, 372-379.	0.5	46
52	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2019, 108, 26-36.	1.2	46
53	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. <i>Annals of Surgery</i> , 2020, 271, 527-533.	2.1	44
54	Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. <i>Neuroendocrinology</i> , 2020, 110, 616-629.	1.2	43

#	ARTICLE	IF	CITATIONS
55	Preoperative versus postoperative docetaxel+cisplatin+fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. <i>Annals of Oncology</i> , 2016, 27, 668-673.	0.6	42
56	CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 270-274.	1.4	41
57	5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)+cisplatin in advanced gastric carcinoma: a phase II trial. <i>Annals of Oncology</i> , 2004, 15, 759-764.	0.6	41
58	Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2007, 39, 537-543.	0.4	40
59	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , 2016, 51, 131-139.	1.1	40
60	Capecitabine Initially Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 421-427.	0.4	38
61	ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 159-165.	1.1	38
62	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018, 107, 237-245.	1.2	37
63	Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 110-124.	2.0	36
64	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , 2010, 36, S87-S94.	3.4	36
65	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?. <i>Annals of Oncology</i> , 1998, 9, 917-919.	0.6	35
66	Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. <i>Neuroendocrinology</i> , 2018, 106, 211-220.	1.2	35
67	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	1.1	33
68	The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 65-75.	2.0	32
69	Should platinum-based chemotherapy be preferred for germline BRCA1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 80, 101895.	3.4	32
70	Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. <i>Endocrine-Related Cancer</i> , 2019, 26, 391-403.	1.6	32
71	Treatments for colorectal liver metastases: A new focus on a familiar concept. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 154-163.	2.0	31
72	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , 2017, 56, 633-638.	1.1	30

#	ARTICLE	IF	CITATIONS
73	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016, 103, 531-537.	1.2	28
74	Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. <i>Human Pathology</i> , 2014, 45, 665-673.	1.1	27
75	Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2019, 109, 100-112.	1.2	27
76	Grading lung neuroendocrine tumors: Controversies in search of a solution. <i>Histology and Histopathology</i> , 2017, 32, 223-241.	0.5	27
77	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	0.6	26
78	Cost Effectiveness of Different Central Venous Approaches for Port Placement and Use in Adult Oncology Patients: Evidence From a Randomized Three-Arm Trial. <i>Annals of Surgical Oncology</i> , 2014, 21, 3725-3731.	0.7	26
79	Unmet Needs in Appendiceal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2019, 108, 37-44.	1.2	26
80	Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4106-4106.	0.8	25
81	Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. <i>European Journal of Endocrinology</i> , 2020, 182, 439-446.	1.9	24
82	Practical Considerations in the Treatment of Hepatocellular Carcinoma. <i>Drugs</i> , 1998, 55, 367-382.	4.9	23
83	High Intensity Focused Ultrasound Ablation of Pancreatic Neuroendocrine Tumours: Report of Two Cases. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 419-423.	0.9	23
84	Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials. <i>Acta Oncologica</i> , 2003, 42, 693-700.	0.8	22
85	Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003. <i>International Journal of Colorectal Disease</i> , 2005, 20, 221-230.	1.0	22
86	Perfusion Computed Tomography in Patients With Hepatocellular Carcinoma Treated With Thalidomide. <i>Journal of Computer Assisted Tomography</i> , 2011, 35, 195-201.	0.5	22
87	Prognostic value of human papillomavirus in anal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1033-1038.	1.1	22
88	RAF signaling in neuroendocrine neoplasms: From bench to bedside. <i>Cancer Treatment Reviews</i> , 2014, 40, 974-979.	3.4	21
89	ecancermedalscience. <i>Ecancermedalscience</i> , 2011, 5, 201.	0.6	20
90	Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making. <i>International Journal of Surgery</i> , 2015, 20, 58-64.	1.1	20

#	ARTICLE	IF	CITATIONS
91	Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Targeted Oncology, 2017, 12, 611-622.	1.7	20
92	Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2015, 41, 754-760.	3.4	19
93	Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. Critical Reviews in Oncology/Hematology, 2016, 99, 1-12.	2.0	19
94	Alpelisib in combination with everolimus±Axemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. European Journal of Cancer, 2021, 151, 49-62.	1.3	19
95	Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. Annals of Oncology, 2003, 14, 803-804.	0.6	18
96	Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Annals of Oncology, 2006, 17, 1174-1175.	0.6	18
97	The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. Journal of Thoracic Disease, 2017, 9, S1501-S1510.	0.6	18
98	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	0.5	18
99	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 607-618.	1.6	18
100	Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE) Tj ETQq0 0 0 0 BT /Overlock 10 Tf 5	0.5	18
101	No impact of central venous insertion site on oncology patientsâ€™ quality of life and psychological distress. A randomized three-arm trial. Supportive Care in Cancer, 2011, 19, 1573-1580.	1.0	17
102	Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. Journal of Endocrinological Investigation, 2014, 37, 875-909.	1.8	17
103	Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. Lung Cancer, 2020, 148, 149-158.	0.9	16
104	Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib. Targeted Oncology, 2021, 16, 27-35.	1.7	16
105	ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology. Journal of Neuroendocrinology, 2022, 34, e13100.	1.2	16
106	Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. Cancer Treatment Reviews, 2017, 57, 28-35.	3.4	15
107	A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. Journal of Thoracic Disease, 2018, 10, 3928-3939.	0.6	15
108	Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 993-1004.	1.5	15

#	ARTICLE	IF	CITATIONS
109	Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 39-46.	3.4	14
110	Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 301-306.	1.1	13
111	Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms. <i>Pancreas</i> , 2021, 50, 727-731.	0.5	13
112	Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 139-148.	1.1	12
113	First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3659-3659.	0.8	12
114	Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: A difficult conversion from biology to the clinic. <i>World Journal of Clinical Oncology</i> , 2015, 6, 194.	0.9	12
115	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13105.	1.2	12
116	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	1.3	11
117	Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?. <i>International Journal of Oncology</i> , 2016, 48, 1280-1289.	1.4	10
118	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. <i>Endocrine</i> , 2021, 72, 268-278.	1.1	10
119	Capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NEN): An Italian multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 281-281.	0.8	10
120	Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4102-4102.	0.8	10
121	Molecular Targeted Therapy in Enteropancreatic Neuroendocrine Tumors: From Biology to Clinical Practice. <i>Current Medicinal Chemistry</i> , 2014, 21, 1017-1025.	1.2	10
122	Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 59, 446-54.	0.4	10
123	Gastroenteropancreatic Neuroendocrine Carcinomas: The NET G3 Subcategory Is a Reality. <i>Oncologist</i> , 2017, 22, 359-359.	1.9	9
124	Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 292-299.	1.8	9
125	Results of Surgical Resection of Locally Advanced Pulmonary Neuroendocrine Tumors. <i>Annals of Thoracic Surgery</i> , 2021, 112, 405-414.	0.7	9
126	5FU as protracted continuous IV infusion (5FU <sub>piv</sub> ) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC). <i>European Journal of Cancer</i> , 1999, 35, S139.	1.3	8



#	ARTICLE	IF	CITATIONS
127	Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 573-574.	0.8	8
128	Human papillomavirus in anal squamous cell carcinoma: an angel rather than a devil?. <i>Ecancermedalscience</i> , 2015, 9, 529.	0.6	8
129	Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report. <i>Ecancermedalscience</i> , 2016, 10, 635.	0.6	8
130	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5013-5030.	1.0	8
131	First <i>Ex Vivo</i> Results of $\hat{I}^2$ -Radioguided Surgery in Small Intestine Neuroendocrine Tumors with $^{90}\text{Y}$ -DOTATOC. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 397-406.	0.7	8
132	Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4090-4090.	0.8	8
133	Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. <i>Supportive Care in Cancer</i> , 2005, 13, 194-195.	1.0	7
134	Successful chemotherapy and $^{90}\text{Y}$ -DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. <i>Acta Oncologica</i> , 2006, 45, 627-629.	0.8	7
135	Miliary Hepatic Metastases from Neuroendocrine Carcinoma. <i>Digestive Surgery</i> , 2008, 25, 330-330.	0.6	7
136	Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives. <i>Cancer Treatment Reviews</i> , 2017, 55, 46-56.	3.4	7
137	Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. <i>Pharmaceuticals</i> , 2021, 14, 539.	1.7	7
138	Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 317-325.	1.8	7
139	Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102261.	3.4	7
140	Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 1758835921110295.	1.4	7
141	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , 2022, 14, 2501.	1.7	7
142	Temsirolimus for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 357, 1050-1051.	13.9	6
143	Successful Treatment with GEMOX in Patient with Metastatic Pancreatic Adenosquamous Carcinoma. <i>Tumori</i> , 2011, 97, 239-242.	0.6	6
144	A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 161-168.	2.0	6

#	ARTICLE	IF	CITATIONS
145	Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. <i>Future Oncology</i> , 2019, 15, 1997-2007.	1.1	6
146	Ivosidenib for advanced IDH1-mutant cholangiocarcinoma. <i>Lancet Oncology</i> , The, 2020, 21, e370.	5.1	6
147	Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2 Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?. <i>Journal of Clinical Oncology</i> , 2020, 38, 2466-2467.	0.8	6
148	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 94, 102168.	3.4	6
149	Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4136-4136.	0.8	6
150	The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 380-380.	0.8	6
151	The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review. <i>Ecancermedalscience</i> , 2020, 14, 1123.	0.6	6
152	Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma—Is It Based on Evidence or Clinical Wisdom?. <i>JAMA Oncology</i> , 2021, 7, 1759.	3.4	6
153	Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. <i>Anticancer Research</i> , 2003, 23, 5023-30.	0.5	6
154	ecancermedalscience. <i>Ecancermedalscience</i> , 2012, 6, 240.	0.6	5
155	ecancermedalscience. <i>Ecancermedalscience</i> , 2010, 4, 197.	0.6	5
156	Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. <i>Anti-Cancer Drugs</i> , 2008, 19, 837-840.	0.7	5
157	Regression of advanced neuroendocrine tumors among patients receiving placebo. <i>Endocrine-Related Cancer</i> , 2017, 24, L13-L16.	1.6	5
158	Multidisciplinary team approach for Merkel cell carcinoma: the European Institute of Oncology experience with focus on radiotherapy. <i>Tumori</i> , 2021, 107, 145-149.	0.6	5
159	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , 2021, 19, 70.	1.8	5
160	A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. <i>Diagnostics</i> , 2021, 11, 804.	1.3	5
161	Carboplatin with etoposide in patients with extrapulmonary "aggressive" neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2010, 28, e13072-e13072.	0.8	5
162	Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).. <i>Journal of Clinical Oncology</i> , 2019, 37, 332-332.	0.8	5

#	ARTICLE	IF	CITATIONS
163	Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and EpiDoxorubicin in a Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 1345-1346.	3.0	4
164	Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 18, 419-449.	0.6	4
165	G3 GEP NENs category: are basic and clinical investigations well integrated?. Endocrine, 2018, 60, 28-30.	1.1	4
166	<p></p>Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature</p>. Lung Cancer: Targets and Therapy, 2020, Volume 11, 41-52.	1.3	4
167	Outcomes of smallâ€cell versus largeâ€cell gastroenteropancreatic neuroendocrine carcinomas: A populationâ€based study. Journal of Neuroendocrinology, 2021, 33, e12971.	1.2	4
168	Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANTâ€3 and RADIANTâ€4 trials. Cancer, 2021, 127, 2674-2682.	2.0	4
169	Prognostic features of gastroâ€enteroâ€pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties. Journal of Neuroendocrinology, 2021, 33, e13000.	1.2	4
170	Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. European Journal of Cancer, 2021, 154, 246-252.	1.3	4
171	Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib.. Journal of Clinical Oncology, 2019, 37, 4109-4109.	0.8	4
172	Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis. Cancer Treatment Reviews, 2022, 104, 102338.	3.4	4
173	Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors. Updates in Surgery, 2022, 74, 1697-1704.	0.9	4
174	Sex-based differences in the outcomes of patients with lung carcinoids. Journal of Comparative Effectiveness Research, 2022, 11, 523-531.	0.6	4
175	ecancermedalscience. Ecanermedalscience, 2012, 6, 280.	0.6	3
176	No Effect of Cloricromen on Some Coagulation Parameters in Patients with Ischaemic Cerebrovascular Disease. Journal of International Medical Research, 1994, 22, 287-291.	0.4	3
177	When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?. Journal of Clinical Oncology, 2017, 35, 1487-1488.	0.8	3
178	Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?. Current Treatment Options in Oncology, 2021, 22, 19.	1.3	3
179	Watch and waitpolicy in advanced neuroendocrine tumors: What does it mean?. World Journal of Clinical Oncology, 2017, 8, 96.	0.9	3
180	Activity and Tolerability of Courses of Intra-Arterial Chemotherapy Followed by Chemoembolization in Unresectable Hepatocellular Carcinoma. Tumori, 1998, 84, 673-676.	0.6	2

#	ARTICLE	IF	CITATIONS
181	Target-Treatment and Patients' Selection: Can We Still Neglect the Timing of Tissue Collection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6274-6275.	0.8	2
182	Langerhans' cell histiocytosis. <i>Lancet, The</i> , 2005, 365, 598.	6.3	2
183	Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinoma. <i>Acta OncolÃ³gica</i> , 2007, 46, 1205-1206.	0.8	2
184	Clinical Response after Sorafenib for Hepatocellular Carcinoma in Elderly Patients: A Report of Two Cases. <i>Tumori</i> , 2012, 98, e53-e56.	0.6	2
185	Real-world analysis on the use of somatostatin analogs (SSAs) in patients with neuroendocrine neoplasms (NENs): results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Annals of Oncology</i> , 2016, 27, iv114.	0.6	2
186	SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view. <i>Endocrine</i> , 2020, 70, 6-10.	1.1	2
187	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. <i>Future Oncology</i> , 2020, 16, 2089-2099.	1.1	2
188	Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4113-4113.	0.8	2
189	Looking for the right TNM staging system for pancreatic neuroendocrine tumors. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 382-384.	0.7	2
190	Thalidomide in patients with advanced hepatocellular carcinoma: A clinical/biological study. <i>Journal of Clinical Oncology</i> , 2007, 25, 15076-15076.	0.8	2
191	Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside. <i>Current Oncology Reports</i> , 2022, 24, 715-722.	1.8	2
192	CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. <i>Annals of Oncology</i> , 2004, 15, 1850.	0.6	1
193	Bone metastases in patients with neuroendocrine neoplasms: A survey of natural history and clinical management. <i>Annals of Oncology</i> , 2017, 28, v149.	0.6	1
194	Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): Real-world findings from two European neuroendocrine tumour society centres of excellence. <i>Annals of Oncology</i> , 2018, 29, viii472.	0.6	1
195	Personalizing Multimodal Treatment in Patients With Pancreatic Neuroendocrine Tumors. <i>JCO Oncology Practice</i> , 2020, 16, 729-730.	1.4	1
196	Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15160-e15160.	0.8	1
197	Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 303-310.	1.0	1
198	A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3). <i>Diagnostics</i> , 2021, 11, 2401.	1.3	1

#	ARTICLE	IF	CITATIONS
199	Right pelvic mass in a patient with a radically resected carcinoid of the appendix. <i>Gut</i> , 2009, 58, 1200-1200.	6.1	0
200	La terapia medica dei tumori neuroendocrini. <i>L Endocrinologo</i> , 2012, 13, 158-162.	0.0	0
201	Nonfunctioning Pancreatic Neuroendocrine Tumors. , 2015, , 275-298.		0
202	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs). <i>Annals of Oncology</i> , 2016, 27, vi145.	0.6	0
203	HER2/HER3 pathway in biliary tract cancers: A systematic review and meta-analysis. A novel therapeutic druggable target?. <i>Annals of Oncology</i> , 2016, 27, vi237.	0.6	0
204	Validation of a risk-assessment score for prediction of venous thromboembolism in cancer outpatients receiving active treatments: ONKOTEV-2 trial. <i>Annals of Oncology</i> , 2016, 27, vi521.	0.6	0
205	Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial. <i>Annals of Oncology</i> , 2016, 27, vi138.	0.6	0
206	Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 525-536.	0.5	0
207	High-risk human papillomavirus in anal squamous cell carcinoma: a "conservative" leading role. <i>Annals of Oncology</i> , 2017, 28, 1160.	0.6	0
208	Should cT2N0M0 be managed as a localized or locally advanced esophageal carcinoma?. <i>Journal of Thoracic Disease</i> , 2017, 9, 2829-2834.	0.6	0
209	Liver Resection or Resection plus Intraoperative Echo-Guided Ablation in the Treatment of Colorectal Metastases: We are Evaluating Their Effect for Cure. <i>American Surgeon</i> , 2018, 84, 1509-1517.	0.4	0
210	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2317-2324.	0.9	0
211	Mixed Neuroendocrine and Non-neuroendocrine Neoplasms (Mi NEN). , 2021, , 269-282.		0
212	Reply to comments on "COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)". <i>European Journal of Cancer</i> , 2021, 157, 531-532.	1.3	0
213	Neuroendocrine Neoplasms (NENs). <i>UNIPA Springer Series</i> , 2021, , 1061-1089.	0.1	0
214	ECF can be used as adjuvant treatment for oesophagogastric adenocarcinoma: A two-institutions experience. <i>Journal of Clinical Oncology</i> , 2004, 22, 4251-4251.	0.8	0
215	Irinotecan combined with infusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 4146-4146.	0.8	0
216	Should interferon- and somatostatin analogs be combined in gastroenteropancreatic neuroendocrine tumor therapy?. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 229-235.	0.2	0

#	ARTICLE	IF	CITATIONS
217	Hepatic intra-arterial chemotherapy in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 10581-10581.	0.8	0
218	Response to Neo-Adjuvant Chemotherapy for Colorectal Cancer Liver Metastases: A Key for Improving Survival?. <i>Ecancermedalscience</i> , 2009, 1, 58.	0.6	0
219	Vinorelbine, cisplatin, and continuous infusion of 5-fluorouracil (ViFuP regimen) in carcinoma of unknown primary. <i>Journal of Clinical Oncology</i> , 2009, 27, e20682-e20682.	0.8	0
220	Merkel cell polyomavirus in gastrointestinal neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4120-4120.	0.8	0
221	Long-term survival after multidisciplinary treatment of small-bowel neuroendocrine tumors with synchronous liver metastases. AA single-institute experience.. <i>Journal of Clinical Oncology</i> , 2013, 31, 299-299.	0.8	0
222	Long-term survival after multidisciplinary treatment of small-bowel neuroendocrine tumors with synchronous liver metastases: A single-institute experience.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15147-e15147.	0.8	0
223	Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids. <i>European Oncology and Haematology</i> , 2015, 11, 100.	0.0	0
224	Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 5-years update.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4092-4092.	0.8	0
225	Therapy for Metastatic Disease with Unknown Primary Tumor. , 2018, , 335-342.		0
226	Sunitinib in patients with pancreatic neuroendocrine tumors (panNETs): Exploratory pharmacogenomic analyses.. <i>Journal of Clinical Oncology</i> , 2019, 37, 255-255.	0.8	0
227	Irinotecan combined with infusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 4146-4146.	0.8	0
228	ECF can be used as adjuvant treatment for oesophagogastric adenocarcinoma: A two-institutions experience. <i>Journal of Clinical Oncology</i> , 2004, 22, 4251-4251.	0.8	0
229	Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases. <i>Tumori</i> , 2012, 98, 53e-56e.	0.6	0